Terns Pharmaceuticals, Inc. (TERN) EBIT (2020 - 2023)
Terns Pharmaceuticals (TERN) has disclosed EBIT for 4 consecutive years, with -$24.1 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, EBIT fell 42.96% year-over-year to -$24.1 million, compared with a TTM value of -$96.5 million through Dec 2023, down 55.63%, and an annual FY2024 reading of -$88.6 million, up 13.62% over the prior year.
- EBIT was -$24.1 million for Q4 2023 at Terns Pharmaceuticals, up from -$33.2 million in the prior quarter.
- Across five years, EBIT topped out at -$8.7 million in Q3 2020 and bottomed at -$33.2 million in Q3 2023.
- Average EBIT over 4 years is -$15.3 million, with a median of -$13.9 million recorded in 2021.
- The sharpest move saw EBIT decreased 3.98% in 2022, then crashed 91.9% in 2023.
- Year by year, EBIT stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then crashed by 42.96% to -$24.1 million in 2023.
- Business Quant data shows EBIT for TERN at -$24.1 million in Q4 2023, -$33.2 million in Q3 2023, and -$17.8 million in Q2 2023.